qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:4b4485be409990d72a811e7f | QAG:b146fdc4aab9f16ca6f4ab29 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "showed that PD-L1 overexpression was associated with poor prognosis in patients with CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evide... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:193108dcca2db9d5f4ac9c28","quotes":["A meta-analysis by Cao et al. [ 36 ] showed that PD-L1 overexpression was as... | [
"CLM:193108dcca2db9d5f4ac9c28",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC9549670"
] | [
"SPAN:406cbd4edeb486ab7da6d824"
] | [] | [] | {"qa_id":"QA:4b4485be409990d72a811e7f","qa_group_id":"QAG:b146fdc4aab9f16ca6f4ab29","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"showed that PD-L1 overexpression was associated with poor prognosi... |
QA:4be4f03500cf97243e855397 | QAG:96b503c3c19ecbbe49a3f572 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The Japanese REGONIVO study showed an ORR of 33% in advanced CRC patients with MSS status who received nivolumab and regorafenib"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact support... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:d7ad8be047501eb2318af77f","quotes":["The Japanese REGONIVO study showed an ORR of 33% in advanced CRC patients wi... | [
"CLM:d7ad8be047501eb2318af77f",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9549670"
] | [
"SPAN:9e3772d731712906182a832d"
] | [] | [] | {"qa_id":"QA:4be4f03500cf97243e855397","qa_group_id":"QAG:96b503c3c19ecbbe49a3f572","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The Japanese REGONIVO study showed an ORR of 33% in advanced CRC p... |
QA:4c51882a7b7442908c7d94f2 | QAG:04c8860696eab08c39bd5140 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The expression level of PD-L1 in TCs or ICs was correlated with tumor size in dMMR CRC ( P = 0.034 and P = 0.019, respectively), and the expression level of PD-L1 in TCs was related to tumor size and histological classification in pMMR CRC ( P = 0.020 and P = 0.025), w... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:eb4a62de54fa1aaae34dc690","quotes":["The expression level of PD-L1 in TCs or ICs was correlated with tumor size i... | [
"CLM:eb4a62de54fa1aaae34dc690",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:1c39acda717014ccb4a0e0e1"
] | [] | [] | {"qa_id":"QA:4c51882a7b7442908c7d94f2","qa_group_id":"QAG:04c8860696eab08c39bd5140","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The expression level of PD-L1 in TCs or ICs was correlated with tu... |
QA:4ddba2c8d9a131e51657dffa | QAG:d4fa12e4537078afd7845bb5 | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33837064? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:33837064","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:33837064"
] | [] | [] | [] | {"qa_id":"QA:4ddba2c8d9a131e51657dffa","qa_group_id":"QAG:d4fa12e4537078afd7845bb5","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:33837064? E... |
QA:4ea1e70c8883c86352390839 | QAG:de4e024f74e20ee5827828eb | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "This study was conducted following the Declaration of Helsinki and received the full approval of the Sun Yat-sen University Cancer Center Institutional Review Board on Medical Ethics (B2020-141-01)"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:59264b508ad697e4377ce21d","quotes":["This study was conducted following the Declaration of Helsinki and received ... | [
"CLM:59264b508ad697e4377ce21d",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8714781"
] | [
"SPAN:ccb33c7a5cf99f7e44037cb1",
"SPAN:d1f2027642f7d590bcdd461e"
] | [] | [] | {"qa_id":"QA:4ea1e70c8883c86352390839","qa_group_id":"QAG:de4e024f74e20ee5827828eb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"This study was conducted following the Declaration of Helsinki and... |
QA:533fd34214d4181847060d37 | QAG:27ad69b462bcd20b178ddad5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "However, previous reports demonstrated that front line use of PD-1 blockade was associated with a higher response rate compared with a late line either in Non–Small-Cell lung cancer or metastatic colorectal cancer, 3 , 4 suggesting that early use of PD-1 antibody might... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8902dcb5910382d8ba9c78d5","quotes":["However, previous reports demonstrated that front line use of PD-1 blockade ... | [
"CLM:8902dcb5910382d8ba9c78d5",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC6984585"
] | [
"SPAN:96baac16a911b2e85bb64c86"
] | [] | [] | {"qa_id":"QA:533fd34214d4181847060d37","qa_group_id":"QAG:27ad69b462bcd20b178ddad5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"However, previous reports demonstrated that front line use of PD-1... |
QA:53818f9cbf7140231a998b19 | QAG:edb5082d2958eab8ea7cdde7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Here we describe a patient with MSI-H colorectal cancer that received this immune checkpoint inhibitor and exhibited progression of disease"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ex... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c7546e3e2be0760d3e083c23","quotes":["Here we describe a patient with MSI-H colorectal cancer that was treated wit... | [
"CLM:c7546e3e2be0760d3e083c23",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC6679789"
] | [
"SPAN:f09a77aac628db63a287a17f"
] | [] | [] | {"qa_id":"QA:53818f9cbf7140231a998b19","qa_group_id":"QAG:edb5082d2958eab8ea7cdde7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Here we describe a patient with MSI-H colorectal cancer that recei... |
QA:58d26fce22a84557f008a69c | QAG:f6d8f6b7e2fc408e9c8b1130 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Meanwhile, patients with dMMR/MSI⁃H pathological stage III CRC who received adjuvant chemotherapy have better prognoses than MSS patients ( 28 , 29 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:95cc5dc200d9d854cb6015e7","quotes":["Meanwhile, patients with dMMR/MSI⁃H pathological stage III CRC who received ... | [
"CLM:95cc5dc200d9d854cb6015e7",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9359076"
] | [
"SPAN:8bf13e486c44fadd3fd26f0f"
] | [] | [] | {"qa_id":"QA:58d26fce22a84557f008a69c","qa_group_id":"QAG:f6d8f6b7e2fc408e9c8b1130","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Meanwhile, patients with dMMR/MSI⁃H pathological stage III CRC who... |
QA:5984824619dec570702f2525 | QAG:ae0f9757f80be54ece0ff1be | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "All these favorable results in dMMR/MSI-H CRC contrast sharply with those of later-line conventional chemotherapy for overall mCRC with treatments such as regorafenib or TAS-102, which led to ORR of only 1% and median PFS of around 2 months"? Return the original wordin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:497f5dbb91a70061d9b1d41f","quotes":["All these favorable results in dMMR/MSI-H CRC contrast sharply with those of... | [
"CLM:497f5dbb91a70061d9b1d41f",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC7577804"
] | [
"SPAN:ae21c56d8bbf0b7ead13aa19"
] | [] | [] | {"qa_id":"QA:5984824619dec570702f2525","qa_group_id":"QAG:ae0f9757f80be54ece0ff1be","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"All these favorable results in dMMR/MSI-H CRC contrast sharply wit... |
QA:5bf7e45c8e45e77641cf7ff2 | QAG:677a0a2fdf4d1e622d682e19 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "However, a high density of CD68 + and CD163 + macrophages was not associated with clinical parameters in either dMMR or pMMR CRC (Supplementary Tables 6–7)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirement... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:52377ee81babb74ea14c090c","quotes":["However, a high density of CD68 + and CD163 + macrophages was not associated... | [
"CLM:52377ee81babb74ea14c090c",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:480b22cec556dcd935f923ca"
] | [] | [] | {"qa_id":"QA:5bf7e45c8e45e77641cf7ff2","qa_group_id":"QAG:677a0a2fdf4d1e622d682e19","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"However, a high density of CD68 + and CD163 + macrophages was not ... |
QA:5d181432d4adcbee6313f0de | QAG:3993dd09deea47b0bb240394 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Very importantly, the expression of PD-L1 was markedly decreased in ZG16-overexpressed SW480 cells, indicating that PD-L1 is directly regulated by ZG16 in colon cancer ( Fig. 2 A)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrate... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:860cb9fa31c763fd2d0e2919","quotes":["Very importantly, the expression of PD-L1 was markedly decreased in ZG16-ove... | [
"CLM:860cb9fa31c763fd2d0e2919",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC7773682"
] | [
"SPAN:1e655291bde2e4c633a4d19a"
] | [] | [] | {"qa_id":"QA:5d181432d4adcbee6313f0de","qa_group_id":"QAG:3993dd09deea47b0bb240394","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Very importantly, the expression of PD-L1 was markedly decreased i... |
QA:5e0e9b7fcdd9faf57ba5af69 | QAG:73d7f3dc33f4f96828f6b2a2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Previous studies have suggested that IL-1β could promote the invasion and growth of human colon cancer cells , and IL-1β polymorphisms was associated with CRC recurrence"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenan... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:64eb8b6e1e6f40ca899f0a61","quotes":["Previous studies have suggested that IL-1β could promote the invasion and gr... | [
"CLM:64eb8b6e1e6f40ca899f0a61",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10142806"
] | [
"SPAN:04bb1f424e6aa7452f5033e3"
] | [] | [] | {"qa_id":"QA:5e0e9b7fcdd9faf57ba5af69","qa_group_id":"QAG:73d7f3dc33f4f96828f6b2a2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Previous studies have suggested that IL-1β could promote the invas... |
QA:6161f9587e513dec318e317b | QAG:31bb7a092f01d37720954e02 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Immunotherapy has achieved durable responses in a subset of patients with dMMR-MSI-H metastatic CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a83056f928cc7ef522bf6d4a","quotes":["Immunotherapy has achieved durable responses in a subset of patients with dM... | [
"CLM:a83056f928cc7ef522bf6d4a",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC7773682"
] | [
"SPAN:c58682bd4f0a054a43359b15"
] | [] | [] | {"qa_id":"QA:6161f9587e513dec318e317b","qa_group_id":"QAG:31bb7a092f01d37720954e02","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Immunotherapy has achieved durable responses in a subset of patien... |
QA:634c45f468695d73f04616d2 | QAG:0e00b639bfccf30437a01965 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Mucinous and signet-ring cell histology, which was associated with poor survival outcomes in the multivariate analysis, were also more common in association with MSI-H CRC (33.3%) than with MSS or MSI-L tumors (18.2%) ( S2 Table ); these findings aligned with the propo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:365fb169441ae13dda91b96e","quotes":["Mucinous and signet-ring cell histology, which were independently associated... | [
"CLM:365fb169441ae13dda91b96e",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:88bcf972a5c085367c7a638b"
] | [] | [] | {"qa_id":"QA:634c45f468695d73f04616d2","qa_group_id":"QAG:0e00b639bfccf30437a01965","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Mucinous and signet-ring cell histology, which was associated with... |
QA:657dad0c18131df8cc3b8c55 | QAG:0de38402e121638561a119b6 | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9741977? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9741977","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9741977"
] | [] | [] | [] | {"qa_id":"QA:657dad0c18131df8cc3b8c55","qa_group_id":"QAG:0de38402e121638561a119b6","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9741977... |
QA:674db93dda35ef2168d77e3e | QAG:0f6076b573c3329eeb77a4d7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Conclusion dMMR was associated with an improved prognosis in stage II colon cancer but is no longer associated with a favorable prognosis in stage III colon cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance req... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a125fbe200c1f9d3ce5d545b","quotes":["Conclusion dMMR is associated with an improved prognosis in stage II colon c... | [
"CLM:a125fbe200c1f9d3ce5d545b"
] | [
"PMCID:PMC9468812"
] | [
"SPAN:b01a545c2ed68ff6e11f9f17"
] | [] | [] | {"qa_id":"QA:674db93dda35ef2168d77e3e","qa_group_id":"QAG:0f6076b573c3329eeb77a4d7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Conclusion dMMR was associated with an improved prognosis in stage... |
QA:68b4d094f484b8120972fc34 | QAG:e0e2cacf428c95fac2030c92 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Although diagnosis and treatment strategies for CRC have improved rapidly in recent years, the prognosis is unfavorable for many CRC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:4101fa83b52b24b0d3a57914","quotes":["Although diagnosis and treatment strategies for CRC have improved rapidly in... | [
"CLM:4101fa83b52b24b0d3a57914",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10142806"
] | [
"SPAN:1dc1427043e45d03a4808176"
] | [] | [] | {"qa_id":"QA:68b4d094f484b8120972fc34","qa_group_id":"QAG:e0e2cacf428c95fac2030c92","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Although diagnosis and treatment strategies for CRC have improved ... |
QA:69f4653c7847c3ca15933471 | QAG:397fca34a0925e220427f4af | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In terms of Crohn-like lymphoid aggregates, a previous study showed that the formation of ectopic lymphoid tissues was correlated with better CRC survival outcomes, although none of the patients had received treatment with ICIs"? Return the original wording with paper,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dd1b9727ca0c956fadb91331","quotes":["In terms of Crohn-like lymphoid aggregates, a previous study showed that the... | [
"CLM:dd1b9727ca0c956fadb91331",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:fb0d2876781361c7b8fcead8"
] | [] | [] | {"qa_id":"QA:69f4653c7847c3ca15933471","qa_group_id":"QAG:397fca34a0925e220427f4af","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In terms of Crohn-like lymphoid aggregates, a previous study showe... |
QA:6bde32008f086607b8698a0d | QAG:35bb30a3e61987a9088bf054 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "These findings suggest that ICIs evoke more robust and rapid responses in earlier stages of CRC than observed in the metastatic setting, where a cCR is observed in 13% and 24% of dMMR/MSI-H patients treated with the anti-PD1 pembrolizumab or nivolumab plus the anti-CTL... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3066c16d52bd5dfefcc64730","quotes":["These findings suggest tha... | [
"CLM:3066c16d52bd5dfefcc64730",
"CLM:439debb91a7c2319411d2844",
"CLM:ca96453c9df0277153d763b6",
"CLM:a17b5d1a2a868798b4e8707b",
"CLM:eba667832912dfd0e18bf356"
] | [
"PMCID:PMC9496787",
"PMCID:PMC8714781",
"PMCID:PMC10142806"
] | [
"SPAN:bb1f8e5c077ed3a129b35773",
"SPAN:607f359d4b02a1022877e697",
"SPAN:69049fb9150b33478404d849",
"SPAN:ee3f6b8a83da99edce046e7f"
] | [
"ASC2:381323b8ce032a46326df48f",
"ASC2:15aca1021efc59c7b8889c00"
] | [
"HYP:DCH:8d03e15e539a7efb3c4e75fa",
"HYP:DCH:ebf417f969faed816cfd1237"
] | {"qa_id":"QA:6bde32008f086607b8698a0d","qa_group_id":"QAG:35bb30a3e61987a9088bf054","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"These findings suggest that ICIs evoke more robust and rapid respo... |
QA:6be28821cc255e91afa4ee93 | QAG:56ec55a400fd9423d8f1c8de | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "These results concerning pembrolizumab and nivolumab alone or in combination with ipilimumab in previously treated patients with MSI/dMMR metastatic CRC have led to the approval of these treatments by the Food and Drug Administration (FDA) in the US"? Return the origin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6cc737fd58ed5480bbd68a51","quotes":["These results concerning pembrolizumab and nivolumab alone or in combination... | [
"CLM:6cc737fd58ed5480bbd68a51",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8710086"
] | [
"SPAN:d36e026d04172fef571107e0"
] | [] | [] | {"qa_id":"QA:6be28821cc255e91afa4ee93","qa_group_id":"QAG:56ec55a400fd9423d8f1c8de","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"These results concerning pembrolizumab and nivolumab alone or in c... |
QA:6d3f08d1541184eea10ef812 | QAG:3d2614ef44571dbb7cbfd866 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "MMP9 mediates tumor invasion, metastasis, and immune escape through a pro-oncogenic signaling pathway [ 37 – 39 ] and was associated with relapse and poor prognosis in patients with CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Int... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:62bc9e442035bebefc555e8c","quotes":["MMP9 mediates tumor invasion, metastasis, and immune escape through a pro-on... | [
"CLM:62bc9e442035bebefc555e8c",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10142806"
] | [
"SPAN:086659370982329f0fcf0728"
] | [] | [] | {"qa_id":"QA:6d3f08d1541184eea10ef812","qa_group_id":"QAG:3d2614ef44571dbb7cbfd866","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"MMP9 mediates tumor invasion, metastasis, and immune escape throug... |
QA:7040ad7e4994c3d80f134895 | QAG:76b1ddafc0a63c13cdb285f5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "T3-4 or N1-2 for rectal cancer) or metastasis colorectal cancer with MSI-H or dMMR and received PD-1 antibody as neoadjuvant therapy"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact sup... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1ca1c59b0416664c006bac17","quotes":["Inclusion criteria were: d... | [
"CLM:1ca1c59b0416664c006bac17",
"CLM:439debb91a7c2319411d2844",
"CLM:cf5c154dce106abc969ef0b4",
"CLM:4008e6d923fed22b0792c822"
] | [
"PMCID:PMC6984585",
"PMID:37172580",
"PMCID:PMC9988634"
] | [
"SPAN:5564cf0ccb2088a3d016bbe0",
"SPAN:1c124c4e4a951606fe847840",
"SPAN:05262d9a848532c11dadbe18",
"SPAN:3c3ff17dabcadb323a410fec"
] | [
"ASC2:dcc7164afc030994e06d5b88",
"ASC2:ec570c2fa7c4b3c7f3c52fbf"
] | [
"HYP:DCH:17d05bebf9a5660fb0822edc"
] | {"qa_id":"QA:7040ad7e4994c3d80f134895","qa_group_id":"QAG:76b1ddafc0a63c13cdb285f5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"T3-4 or N1-2 for rectal cancer) or metastasis colorectal cancer wi... |
QA:704db05bedda0940c7f2b65e | QAG:93bdb7001e52d561d679b616 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Abstract Purpose Immune checkpoint blockade has led to a significant improvement of patient survival in metastatic colorectal cancer (CRC) with DNA mismatch repair-deficiency (dMMR)/microsatellite instability-high (MSI-H)"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:503d8e1ae0e1e10584556c80","quotes":["Abstract Purpose Immune checkpoint blockade has led to a significant improve... | [
"CLM:503d8e1ae0e1e10584556c80",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8714781"
] | [
"SPAN:3336ddae1e5582180abd8e55"
] | [] | [] | {"qa_id":"QA:704db05bedda0940c7f2b65e","qa_group_id":"QAG:93bdb7001e52d561d679b616","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Abstract Purpose Immune checkpoint blockade has led to a significa... |
QA:70c6b2d554434a642326be46 | QAG:d7fcfedd03ea0fc83e141fd1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "We previous show that loss of ZG16 was associated with molecular phenotypes of colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, a... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c86b2d12860cfe24f81fbb7b","quotes":["We previous show that loss of ZG16 is associated with molecular phenotypes o... | [
"CLM:c86b2d12860cfe24f81fbb7b",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC7773682"
] | [
"SPAN:af3f3e7adc50f20b357ca8ff"
] | [] | [] | {"qa_id":"QA:70c6b2d554434a642326be46","qa_group_id":"QAG:d7fcfedd03ea0fc83e141fd1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"We previous show that loss of ZG16 was associated with molecular p... |
QA:70e7be6ba6b8749693f4e157 | QAG:a552c1395ef26c3472ab4261 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "(v) received an anti–PD-1 inhibitor either alone (i.e., pembrolizumab or nivolumab) or as combination therapy (i.e., pembrolizumab plus napabucasin; ref"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:348c7a61fb91d919ec827c93","quotes":["The inclusion criteria wer... | [
"CLM:348c7a61fb91d919ec827c93",
"CLM:0995e89bbb1227701c4fcd3a",
"CLM:30cb5b9aef5a73094eadbd23",
"CLM:3066c16d52bd5dfefcc64730"
] | [
"PMCID:PMC9365358",
"PMCID:PMC9820517",
"PMCID:PMC9496787"
] | [
"SPAN:6650fa5a7a345280e93194a4",
"SPAN:4ed1e747d2b038ab634ca148",
"SPAN:bb1f8e5c077ed3a129b35773"
] | [
"ASC2:ea7ced7aceeb2359f8be7772",
"ASC2:444a51ee2c86c93d684fe720"
] | [
"HYP:DCH:acc35a66a95fa0b3c36a0272",
"HYP:DCH:1221a7ffa5ac09471ccb1a0c"
] | {"qa_id":"QA:70e7be6ba6b8749693f4e157","qa_group_id":"QAG:a552c1395ef26c3472ab4261","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"(v) received an anti–PD-1 inhibitor either alone (i.e., pembrolizu... |
QA:712c6a569096f6f1b9ba0614 | QAG:ce782a24b0275532d89b54b7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "MSI-H or dMMR was associated with a better prognosis and plays a negative predictive role for adjuvant fluorouracil-based chemotherapy in patients with early stage resected CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7775c6efc3196a332491753f","quotes":["MSI-H or dMMR is associated with a better prognosis and plays a negative pre... | [
"CLM:7775c6efc3196a332491753f",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC10981578"
] | [
"SPAN:19e978e1084ca2788b96e223"
] | [] | [] | {"qa_id":"QA:712c6a569096f6f1b9ba0614","qa_group_id":"QAG:ce782a24b0275532d89b54b7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"MSI-H or dMMR was associated with a better prognosis and plays a n... |
QA:71dbab0995463515789f5fb8 | QAG:704d1a740547630a45e60237 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Nevertheless, overall survival in patients with CRC has improved in recent years , likely due to increased implementation of screening practices and improved therapeutic strategies, including advances in precision medicine and targeted therapies"? Return the original w... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7225187c738444beb04f86db","quotes":["Nevertheless, overall survival in patients with CRC has improved in recent y... | [
"CLM:7225187c738444beb04f86db",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10981578"
] | [
"SPAN:56e74a2f9b27427116de0bd0"
] | [] | [] | {"qa_id":"QA:71dbab0995463515789f5fb8","qa_group_id":"QAG:704d1a740547630a45e60237","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Nevertheless, overall survival in patients with CRC has improved i... |
QA:746d5ce541e9e358a91efc42 | QAG:93c0754fa94c359410cf0ea4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Among the 71 patients with CRC, 30 had received prior therapies including a fluoropyrimidine, oxaliplatin, and irinotecan, 25 had received bevacizumab, seven had received cetuximab, while six had received multi-kinase inhibitors that target vascular endothelial growth ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a05fc39f0a7017b6c3abed76","quotes":["Among the 71 patients with CRC, 30 had received prior therapies including a ... | [
"CLM:a05fc39f0a7017b6c3abed76",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10772321"
] | [
"SPAN:21a9a75472aab3370c9e0fca"
] | [] | [] | {"qa_id":"QA:746d5ce541e9e358a91efc42","qa_group_id":"QAG:93c0754fa94c359410cf0ea4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Among the 71 patients with CRC, 30 had received prior therapies in... |
QA:7702b8eefe91e58746ee6417 | QAG:dc8cc49202cc9e721695ab9b | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In the present study, elevated expression of cGAS and STING was associated with MSI-H colon cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b1bb02d8b769d9edc4c050f4","quotes":["In the present study, elevated expression of cGAS and STING was positively a... | [
"CLM:b1bb02d8b769d9edc4c050f4",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9818394"
] | [
"SPAN:4f8af65a66be729e60b452ea"
] | [] | [] | {"qa_id":"QA:7702b8eefe91e58746ee6417","qa_group_id":"QAG:dc8cc49202cc9e721695ab9b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In the present study, elevated expression of cGAS and STING was as... |
QA:771ee9b97c2627d6a055c7e8 | QAG:63d8d7b3c1628ed7ab0ee65b | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The patients were either treated with pembrolizumab or were enrolled in one of the phase 2 investigator-sponsored clinical trials of other ICIs, including NCT03150706 (avelumab for previously treated dMMR/MSI-H or POLE -mutant colorectal cancer) and NCT-03435107 (durva... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:893173084cb1b7ddae2e6650","quotes":["The patients were either treated with pembrolizumab or were enrolled in one ... | [
"CLM:893173084cb1b7ddae2e6650",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:25dbf4a61b0680baf4713d35"
] | [] | [] | {"qa_id":"QA:771ee9b97c2627d6a055c7e8","qa_group_id":"QAG:63d8d7b3c1628ed7ab0ee65b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The patients were either treated with pembrolizumab or were enroll... |
QA:77ba6233e21088cbf1cb8175 | QAG:50c0a60028cae41964f5ce14 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Similar findings have also been observed in the CheckMate-142 study, in which nivolumab was given to patients with previously treated dMMR/MSI-H CRC, and those with PD-L1 ≥1% achieved an ORR of 29%, while those with PD-L1 <1% achieved an ORR of 28%"? Return the origina... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5d91ad996d5685307c7b2a0a","quotes":["Similar findings have also been observed in the CheckMate-142 study, in whic... | [
"CLM:5d91ad996d5685307c7b2a0a",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC10772321"
] | [
"SPAN:6324fc4eaeb9fc95a4fb3c86"
] | [] | [] | {"qa_id":"QA:77ba6233e21088cbf1cb8175","qa_group_id":"QAG:50c0a60028cae41964f5ce14","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Similar findings have also been observed in the CheckMate-142 stud... |
QA:792cce801c22160f839ecbab | QAG:b35bf9dbff66119f523b6c02 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In the present meta-analysis, the ORR of anti-PD-1/PD-L1 antibody therapy in the treatment of advanced CRC achieved 23%"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:35bb7472db1f235ae970e008","quotes":["In the present meta-analysis, the ORR of anti-PD-1/PD-L1 antibody therapy in... | [
"CLM:35bb7472db1f235ae970e008",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9549670"
] | [
"SPAN:791126225d4ba2f7128ef831"
] | [] | [] | {"qa_id":"QA:792cce801c22160f839ecbab","qa_group_id":"QAG:b35bf9dbff66119f523b6c02","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In the present meta-analysis, the ORR of anti-PD-1/PD-L1 antibody ... |
QA:79856525ef7b6d10420f28b8 | QAG:47056c7d97a398342be64274 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The remaining 268 patients were included from the The Haraldsplass Deaconess Hospital (HDH)–material; a population-based cohort with colon cancer patients recruited from 2007 to 2011 ( 12 , 13 )"? Return the original wording with paper, Claim, and Evidence Span referen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:47dd407ebb9217196f1891b1","quotes":["The remaining 268 patients were included from the The Haraldsplass Deaconess... | [
"CLM:47dd407ebb9217196f1891b1",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC9468812"
] | [
"SPAN:1d67446573d2942fc3319f60"
] | [] | [] | {"qa_id":"QA:79856525ef7b6d10420f28b8","qa_group_id":"QAG:47056c7d97a398342be64274","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The remaining 268 patients were included from the The Haraldsplass... |
QA:7acf0892d33c401de5c9541a | QAG:cac30db05d8757a552cc2c28 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Most importantly, the expression of CMTM6 in M2 macrophages predicted the response rate to PD-1/PD-L1 inhibitors in CRC patients (5/7, 71.4%) more accurately than dMMR/MSI-H status (2/6, 33%)"? Return the original wording with paper, Claim, and Evidence Span references... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:25db4df50d05e8d1968a47c5","quotes":["Most importantly, the expression of CMTM6 in M2 mac... | [
"CLM:25db4df50d05e8d1968a47c5",
"CLM:439debb91a7c2319411d2844",
"CLM:ba0666751d94014de909e19e"
] | [
"PMCID:PMC8505364",
"PMCID:PMC9820517"
] | [
"SPAN:30f45a6513805fc14a7aa299",
"SPAN:4ed1e747d2b038ab634ca148"
] | [
"ASC2:7c3fecea9cbce03747bb32d2"
] | [] | {"qa_id":"QA:7acf0892d33c401de5c9541a","qa_group_id":"QAG:cac30db05d8757a552cc2c28","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Most importantly, the expression of CMTM6 in M2 macrophages predic... |
QA:7beb9c51a4351bf66d701e61 | QAG:6ddddc66d0816249e43a78d0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "As shown in Figures 3(a) and 3(b) , patients without APC mutations did not have prolonged overall survival from TCGA CRC cohort (HR 1.00 (95% CI 0.64–1.56), P > 0.05) and MSKCC pancancer immunotherapy cohort (HR 1.13 (95% CI 0.88–1.45), P > 0.05)"? Return the original ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:443229c7a367bd45b270fdf7","quotes":["As shown in Figures 3(a) and 3(b) , patients without APC mutations did not h... | [
"CLM:443229c7a367bd45b270fdf7",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC9300385"
] | [
"SPAN:fcd791736345d753c0209e97"
] | [] | [] | {"qa_id":"QA:7beb9c51a4351bf66d701e61","qa_group_id":"QAG:6ddddc66d0816249e43a78d0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"As shown in Figures 3(a) and 3(b) , patients without APC mutations... |
QA:7dae67bdf1ae62935e135687 | QAG:474c002f41c563cfa1359ad4 | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35471834? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:35471834","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:35471834"
] | [] | [] | [] | {"qa_id":"QA:7dae67bdf1ae62935e135687","qa_group_id":"QAG:474c002f41c563cfa1359ad4","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:35471834? E... |
QA:7f0608128f3297367f3bc0b5 | QAG:cf691177eeda5b5fb49359e4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "ABSTRACT Background : Although PD-1 blockade has improved the survival of metastatic colorectal cancer with DNA Mismatch Repair-Deficient/Microsatellite Instability-High (MSI-H), the data on neoadjuvant setting is limited"? Return the original wording with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:91e6a32caa40f84b08f4c40e","quotes":["ABSTRACT Background : Although PD-1 blockade has si... | [
"CLM:91e6a32caa40f84b08f4c40e",
"CLM:439debb91a7c2319411d2844",
"CLM:91f035f0a3e5b22bf5c8bdc7"
] | [
"PMCID:PMC6984585",
"PMCID:PMC8714781"
] | [
"SPAN:e5eafaacd07531f0c9c28cf6",
"SPAN:706e106952b373b93b4ddaff"
] | [
"ASC2:1b326b927991e49ca6afeb85"
] | [
"HYP:DCH:b2368124cb2381d95a7217e8"
] | {"qa_id":"QA:7f0608128f3297367f3bc0b5","qa_group_id":"QAG:cf691177eeda5b5fb49359e4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"ABSTRACT Background : Although PD-1 blockade has improved the surv... |
QA:823001688040cf626c5b3ef5 | QAG:b5937a0b675bc0be89a4c04b | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Although ICI treatment was associated with encou-raging results against dMMR/MSI-H metastatic CRC, a considerable portion of patients still do not respond to the treatment, and variable clinical outcomes have been reported from different clinical trials, with response ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a933c11eed55607e6f939ac7","quotes":["Although ICI treatment has been associated with encou-raging results against... | [
"CLM:a933c11eed55607e6f939ac7",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:a70b12cad9e9a41d6491cd5e"
] | [] | [] | {"qa_id":"QA:823001688040cf626c5b3ef5","qa_group_id":"QAG:b5937a0b675bc0be89a4c04b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Although ICI treatment was associated with encou-raging results ag... |
QA:829d2e2828ee01a78f06d62a | QAG:e1257a4a78f77de5a5da7b25 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "ICB, including programmed cell death protein-1 (PD-1) inhibitors and anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies, have improved patients’ survival in DNA mismatch repair-deficiency (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cance... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:91f035f0a3e5b22bf5c8bdc7","quotes":["ICB, including programmed cell death protein-1 (PD-... | [
"CLM:91f035f0a3e5b22bf5c8bdc7",
"CLM:439debb91a7c2319411d2844",
"CLM:3d6765bd51a54b0d16ec7d10"
] | [
"PMCID:PMC8714781",
"PMID:36859628"
] | [
"SPAN:706e106952b373b93b4ddaff",
"SPAN:efa4f4182114c2cf76b6e183"
] | [
"ASC2:950eeae02e4463c4aa341b3f"
] | [] | {"qa_id":"QA:829d2e2828ee01a78f06d62a","qa_group_id":"QAG:e1257a4a78f77de5a5da7b25","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"ICB, including programmed cell death protein-1 (PD-1) inhibitors a... |
QA:8688de47c28dce378e444a2f | QAG:5ad8d250c69b23246b61042f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In addition, patients with pStage 0–III MSI-H CRC who received surgical resection at SCC between 1999 and 2015 were enrolled in the prognostic analysis as the MSI-H cohort (SCC cohort)"? Return the original wording with paper, Claim, and Evidence Span references.
Inte... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:494cc22a9123968a84984cdf","quotes":["In addition, patients with pStage 0–III MSI-H CRC who received surgical rese... | [
"CLM:494cc22a9123968a84984cdf",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8262295"
] | [
"SPAN:b82e3006badbf5a020678453"
] | [] | [] | {"qa_id":"QA:8688de47c28dce378e444a2f","qa_group_id":"QAG:5ad8d250c69b23246b61042f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In addition, patients with pStage 0–III MSI-H CRC who received sur... |
QA:878c8e59c9c608eb60d43d0f | QAG:1747c37ee37632280d27ae00 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The CIBERSORT method was then used to evaluate the effect of CMTM6 on the immune cell composition of 568 CRC samples, with the results that high expression of CMTM6 promoted the infiltration of CD4 memory resting T cells ( P < 0.001) and M2 Macrophage ( P = 0.016), whi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:81500d6d8fa46f8d4c2d4971","quotes":["The CIBERSORT method was then used to evaluate the effect of CMTM6 on the im... | [
"CLM:81500d6d8fa46f8d4c2d4971",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:32bc9efc4489e3e96ee4df04"
] | [] | [] | {"qa_id":"QA:878c8e59c9c608eb60d43d0f","qa_group_id":"QAG:1747c37ee37632280d27ae00","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The CIBERSORT method was then used to evaluate the effect of CMTM6... |
QA:87c3829cdfd9d39cc9d910c7 | QAG:4c54a3beb3f66f9d7442b356 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Moreover, IL-1β-driven infiltration of MDSCs increased anti-PD-1 resistance in MSI-H/dMMR CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5ac06993f5304cdf6a1e85dd","quotes":["Moreover, IL-1β-driven infiltration of MDSCs enhanc... | [
"CLM:5ac06993f5304cdf6a1e85dd",
"CLM:439debb91a7c2319411d2844",
"CLM:02b542ecdd30313379778da4"
] | [
"PMCID:PMC10142806",
"PMID:36030556"
] | [
"SPAN:172526e920fbbabec14bf918",
"SPAN:cd71edbc4e9aefd0a762b6b4"
] | [
"ASC2:af0d17a0fb0c9f4e56b55534"
] | [
"HYP:DCH:2bf6e4feb5ed1185ff217001"
] | {"qa_id":"QA:87c3829cdfd9d39cc9d910c7","qa_group_id":"QAG:4c54a3beb3f66f9d7442b356","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Moreover, IL-1β-driven infiltration of MDSCs increased anti-PD-1 r... |
QA:88ec875eafa3da16816fe463 | QAG:8ddd96f31001ece734a9a045 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Approximately 37 to 41 mutations per megabase may be a cutoff value, and low TMB was associated with poor response to ICIs and worse PFS within the dMMR/MSI-H population, which may be an explanation for the heterogeneity in response in recent clinical trials of dMMR/MS... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:82787b7e1a33b3caafbfc40c","quotes":["Approximately 37 to 41 mutations per megabase may b... | [
"CLM:82787b7e1a33b3caafbfc40c",
"CLM:439debb91a7c2319411d2844",
"CLM:1497adace34bbf19db0c81cf"
] | [
"PMCID:PMC7577804",
"PMCID:PMC10772321"
] | [
"SPAN:88443b46ffe27efa706f988a",
"SPAN:4ac3f2cf444fca911dbda90b"
] | [
"ASC2:5894494c51df71eefbcc087a"
] | [
"HYP:DCH:9b0a136e0d3f93450ee833bd"
] | {"qa_id":"QA:88ec875eafa3da16816fe463","qa_group_id":"QAG:8ddd96f31001ece734a9a045","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Approximately 37 to 41 mutations per megabase may be a cutoff valu... |
QA:8d2386e40f5622c3098cdc4d | QAG:3ae42d241631d09d7c561b20 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "A subsequent multicenter trial of pembrolizumab for dMMR/MSI-H CRC, the KEYNOTE-164 phase II study led to an ORR of 33% and a median PFS of 4.1 months; the 12-month PFS and OS rates were 34% to 41% and 72% to 76%, respectively, according to prior line of treatment"? Re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:545bde35ced9b59b8e23f30b","quotes":["A subsequent multicenter trial of pembrolizumab for... | [
"CLM:545bde35ced9b59b8e23f30b",
"CLM:439debb91a7c2319411d2844",
"CLM:194f9d230043c611cb6689f2"
] | [
"PMCID:PMC7577804",
"PMCID:PMC9582482"
] | [
"SPAN:5398f5469f01d307341faa79",
"SPAN:31c875744ac7e4350dd35f3a"
] | [
"ASC2:e439563bfe1bf9ed8ec20fe9"
] | [
"HYP:DCH:2f844c95d5d553d7b067112e"
] | {"qa_id":"QA:8d2386e40f5622c3098cdc4d","qa_group_id":"QAG:3ae42d241631d09d7c561b20","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"A subsequent multicenter trial of pembrolizumab for dMMR/MSI-H CRC... |
QA:8ef419176add4d16d5d79b44 | QAG:1f56b13e57217713e8d98290 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "however, high expression of CMTM6 promoted the infiltration of CD4 + memory resting T cells ( P < 0.001), while reduced the proportion of CD8 + T cells ( P = 0.031) and regulatory T cells ( P = 0.042) in pMMR CRC (Supplementary Fig. 5c)"? Return the original wording wi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3f3144bf4124d1193be7236a","quotes":["The results showed that there were no types of immune cells affected by CMTM... | [
"CLM:3f3144bf4124d1193be7236a",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:2b62c6c0a3ee5715859610b5"
] | [] | [] | {"qa_id":"QA:8ef419176add4d16d5d79b44","qa_group_id":"QAG:1f56b13e57217713e8d98290","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"however, high expression of CMTM6 promoted the infiltration of CD4... |
QA:8fca09e2dadd3aedaaca8245 | QAG:1e72b2c5acf42ffb39072b4f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Although the trends in survival have improved overall, treatment options for metastatic colorectal cancer remain a challenge; approximately 50% of patients eventually develop metastatic disease, and 35% of patients already present with metastatic disease at diagnosis"?... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f39914b72f834c341548bd71","quotes":["Although the trends in survival have improved overall, treatment options for... | [
"CLM:f39914b72f834c341548bd71",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9818394"
] | [
"SPAN:c5716cc6bd7a3ce0da434efc"
] | [] | [] | {"qa_id":"QA:8fca09e2dadd3aedaaca8245","qa_group_id":"QAG:1e72b2c5acf42ffb39072b4f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Although the trends in survival have improved overall, treatment o... |
QA:9030a4b9aaf28c4a252b9ffe | QAG:d04cacef89dd6a5f8c85a2d5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Background Recent advances in immune checkpoint blockade (ICB) have improved patient prognosis in mismatch repair-deficient and microsatellite instability-high colorectal cancer (dMMR/MSI-H CRC); however, PD-1 blockade has faced a challenge in early progressive disease... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3d6765bd51a54b0d16ec7d10","quotes":["Background Recent advances in immune checkpoint blo... | [
"CLM:3d6765bd51a54b0d16ec7d10",
"CLM:439debb91a7c2319411d2844",
"CLM:37f62821a99d472126d5ed39"
] | [
"PMID:36859628",
"PMCID:PMC9988634"
] | [
"SPAN:efa4f4182114c2cf76b6e183",
"SPAN:2565648bd4a35a448a6e4baf"
] | [
"ASC2:71f9c475c2fb712480d63301"
] | [
"HYP:DCH:71f2303bccbd40db82003ed0"
] | {"qa_id":"QA:9030a4b9aaf28c4a252b9ffe","qa_group_id":"QAG:d04cacef89dd6a5f8c85a2d5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Background Recent advances in immune checkpoint blockade (ICB) hav... |
QA:9705db06fb2a011dfaa57bef | QAG:21a2c978e060fb555d2bb99d | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Preliminary findings of immunotherapy efficacy in localized dMMR/MSI-H CRC cancer stem from post-hoc analyses of the phase-2 NICHE trial, where 2 cycles of nivolumab (anti-PD1) and 1 cycle of ipilimumab (anti-CTLA4) led to a 69% pathological complete response rate (pCR... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:eba667832912dfd0e18bf356","quotes":["Preliminary findings of im... | [
"CLM:eba667832912dfd0e18bf356",
"CLM:439debb91a7c2319411d2844",
"CLM:a17b5d1a2a868798b4e8707b",
"CLM:572fe8772d149aaaee35e012"
] | [
"PMCID:PMC9496787",
"PMCID:PMC10142806",
"PMCID:PMC10772321"
] | [
"SPAN:69049fb9150b33478404d849",
"SPAN:ee3f6b8a83da99edce046e7f",
"SPAN:6324fc4eaeb9fc95a4fb3c86"
] | [
"ASC2:15aca1021efc59c7b8889c00",
"ASC2:5b234a2f8ad271adc2a05bc8"
] | [
"HYP:DCH:976112a22b6530b38a25d640",
"HYP:DCH:180a94b7c86e5fa3ed7c50ba"
] | {"qa_id":"QA:9705db06fb2a011dfaa57bef","qa_group_id":"QAG:21a2c978e060fb555d2bb99d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Preliminary findings of immunotherapy efficacy in localized dMMR/M... |
QA:9876b1a6d6cedf4f847b36c5 | QAG:74cad2763bd5630f59fff83b | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Eight patients received treatment for the purpose of neoadjuvant therapy were identified between 2017 and 2019, from three hospitals in China"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ec6b52ebb33b6d68800f5623","quotes":["We retrospective reviewed all MSI-H colorectal cancer treated with anti-PD-1... | [
"CLM:ec6b52ebb33b6d68800f5623",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC6984585"
] | [
"SPAN:92a6b4edbfad1fb56e7c67dd"
] | [] | [] | {"qa_id":"QA:9876b1a6d6cedf4f847b36c5","qa_group_id":"QAG:74cad2763bd5630f59fff83b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Eight patients received treatment for the purpose of neoadjuvant t... |
QA:995f8661e9fec5df9dff95c0 | QAG:7e5bb6800f7d57e21a151aee | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "one patient failed the screening tests, and thus, 33 patients with histologically or cytologically confirmed, previously treated, metastatic or unresectable CRC were enrolled in the final analysis"? Return the original wording with paper, Claim, and Evidence Span refer... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f90ec29c1c3f36546f1796af","quotes":["Between May 2017 and April 2019, a total of 34 patients were initially enrol... | [
"CLM:f90ec29c1c3f36546f1796af",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC7577804"
] | [
"SPAN:c4068aa277ba90985a464a42"
] | [] | [] | {"qa_id":"QA:995f8661e9fec5df9dff95c0","qa_group_id":"QAG:7e5bb6800f7d57e21a151aee","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"one patient failed the screening tests, and thus, 33 patients with... |
QA:9a4a95fb1b0c5caa8f8cc0ed | QAG:61fb185a9ccf339e30c99512 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Biallelic ARID1A mutation and CTNNB1 mutation was associated with high and low T cell immune infiltrates, respectively, in MSI-H/dMMR CRC. - Both ARID1A and PTEN biallelic mutations should be further investigated as immunotherapy biomarkers in MSI-H/dMMR CRC. - TMB doe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:30cb5b9aef5a73094eadbd23","quotes":["- Biallelic ARID1A mutation and CTNNB1 mutation are... | [
"CLM:30cb5b9aef5a73094eadbd23",
"CLM:439debb91a7c2319411d2844",
"CLM:1497adace34bbf19db0c81cf"
] | [
"PMCID:PMC9820517",
"PMCID:PMC10772321"
] | [
"SPAN:4ed1e747d2b038ab634ca148",
"SPAN:4ac3f2cf444fca911dbda90b"
] | [
"ASC2:7168a6f75ebeba5b118173e2"
] | [
"HYP:DCH:66ae86e6ecb3e08d33d53d5c"
] | {"qa_id":"QA:9a4a95fb1b0c5caa8f8cc0ed","qa_group_id":"QAG:61fb185a9ccf339e30c99512","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Biallelic ARID1A mutation and CTNNB1 mutation was associated with ... |
QA:9b59d848967da9403ab5cbc9 | QAG:629dd4f7c6cfaf7acffdea72 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supportin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a935dd785ea5728c5b2e6d51","quotes":["Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2016. 23. ... | [
"CLM:a935dd785ea5728c5b2e6d51",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10981578"
] | [
"SPAN:b7ca424bae2babed8caf0538"
] | [] | [] | {"qa_id":"QA:9b59d848967da9403ab5cbc9","qa_group_id":"QAG:629dd4f7c6cfaf7acffdea72","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The predicted impact and cost-effectiveness of systematic testing ... |
QA:9dc5779071f7f34a9ae3112f | QAG:cbc46de531b69da8f7efd04e | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Further comparative analysis indicated that 20 patients with dMMR stage I ~ III colon cancer included in NICHE study received nivolumab [3 mg/kg (day1, day15)] combined with ipilimumab [1 mg/kg (day1)] for 4 weeks, and the pCR rate was 60.0% (12/20) ( 10 ), and 17 pati... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f7035fee7098f4903e366127","quotes":["Further comparative analysis indicated that 20 patients with dMMR stage I ~ ... | [
"CLM:f7035fee7098f4903e366127",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9359076"
] | [
"SPAN:bd98a0239146706542ac5038"
] | [] | [] | {"qa_id":"QA:9dc5779071f7f34a9ae3112f","qa_group_id":"QAG:cbc46de531b69da8f7efd04e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Further comparative analysis indicated that 20 patients with dMMR ... |
QA:9f5de52e639eb593feb40579 | QAG:336268b6d41c8f50accc4a95 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Discordances in MSI-H/dMMR assessment between IHC and PCR was associated with limited benefit to immunotherapy. - Immunotherapy biomarkers in MSI-H/dMMR mCRC should rely on tumour genomic profiles and their dominant immune-contexture"? Return the original wording with ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ba0666751d94014de909e19e","quotes":["- Biallelic ARID1A mutation and CTNNB1 mutation are associated with high and... | [
"CLM:ba0666751d94014de909e19e",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9820517"
] | [
"SPAN:4ed1e747d2b038ab634ca148"
] | [] | [] | {"qa_id":"QA:9f5de52e639eb593feb40579","qa_group_id":"QAG:336268b6d41c8f50accc4a95","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Discordances in MSI-H/dMMR assessment between IHC and PCR was asso... |
QA:a27343994bc390fe776e34fe | QAG:0f59de7b60002180af58a8bf | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The clinical outcomes of metastatic CRC have improved in the last few decades with a tailored approach of systemic treatment combining targeted agents with cytotoxic chemotherapy based on molecular biomarkers"? Return the original wording with paper, Claim, and Evidenc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:061775f3c405076464c3f326","quotes":["The clinical outcomes of metastatic CRC have improved in the last few decade... | [
"CLM:061775f3c405076464c3f326",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:b05ba641824765158b1ecf7d"
] | [] | [] | {"qa_id":"QA:a27343994bc390fe776e34fe","qa_group_id":"QAG:0f59de7b60002180af58a8bf","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The clinical outcomes of metastatic CRC have improved in the last ... |
QA:a371fd36c982557d65d58e62 | QAG:af98bf3e6f5f8fcefbb870cd | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "We utilize single-cell RNA sequencing (scRNA-seq) to investigate the dynamics of immune and stromal cells in 19 patients with d-MMR/MSI-H CRC who received neoadjuvant PD-1 blockade"? Return the original wording with paper, Claim, and Evidence Span references.
Integrat... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:cf5c154dce106abc969ef0b4","quotes":["We utilize single-cell RNA sequencing (scRNA-seq) t... | [
"CLM:cf5c154dce106abc969ef0b4",
"CLM:439debb91a7c2319411d2844",
"CLM:4008e6d923fed22b0792c822"
] | [
"PMID:37172580",
"PMCID:PMC9988634"
] | [
"SPAN:1c124c4e4a951606fe847840",
"SPAN:05262d9a848532c11dadbe18",
"SPAN:3c3ff17dabcadb323a410fec"
] | [
"ASC2:53acd8435007816bc8044a12"
] | [] | {"qa_id":"QA:a371fd36c982557d65d58e62","qa_group_id":"QAG:af98bf3e6f5f8fcefbb870cd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"We utilize single-cell RNA sequencing (scRNA-seq) to investigate t... |
QA:a5527fe52cd0dadcfe3ad315 | QAG:939ef1aa0191fcff08384b94 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "29 , 30 Previous studies have reported that genomic alterations in the KMT2 family was associated with higher frequencies of dMMR/MSI-H and higher TMB in patients with CRC or gastric cancer"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1497adace34bbf19db0c81cf","quotes":["29 , 30 Previous studies have reported that genomic alterations in the KMT2 ... | [
"CLM:1497adace34bbf19db0c81cf",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC10772321"
] | [
"SPAN:4ac3f2cf444fca911dbda90b"
] | [] | [] | {"qa_id":"QA:a5527fe52cd0dadcfe3ad315","qa_group_id":"QAG:939ef1aa0191fcff08384b94","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"29 , 30 Previous studies have reported that genomic alterations in... |
QA:a5b922a3cd22d17ae2a438c8 | QAG:1c2e95190780e1f1ab6ecbe8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The location of cancer in the ascending (RC) colon was associated with the MSI-H type of colon cancer (chi-square test, p ≤ 0.0001)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supp... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ddedba948ce00ccf949e77b1","quotes":["The location of cancer in the ascending (RC) colon was positively associated... | [
"CLM:ddedba948ce00ccf949e77b1",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9818394"
] | [
"SPAN:3306de49a55f3353903dbc49"
] | [] | [] | {"qa_id":"QA:a5b922a3cd22d17ae2a438c8","qa_group_id":"QAG:1c2e95190780e1f1ab6ecbe8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The location of cancer in the ascending (RC) colon was associated ... |
QA:a829bdd98bdfd27c5e62539a | QAG:5ef7b4a8fa60cfb7cacb3ea4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In Kaplan–Meier analysis with the log-rank test, PD-L1 expression did not improve survival in stage II and III colon cancer analyzed together (PD-L1-positive: mean DFS 51.7 months (95% CI 47.4-55.9) vs. PD-L1-negative mean DFS 48.6 months (46.5-50.7), p=0.120) ( Supple... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:55d3861847c2606dbc1938ec","quotes":["In Kaplan–Meier analysis with the log-rank test, PD-L1 expression did not si... | [
"CLM:55d3861847c2606dbc1938ec",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC9468812"
] | [
"SPAN:f73736fe7ea7e0f791fec39f"
] | [] | [] | {"qa_id":"QA:a829bdd98bdfd27c5e62539a","qa_group_id":"QAG:5ef7b4a8fa60cfb7cacb3ea4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In Kaplan–Meier analysis with the log-rank test, PD-L1 expression ... |
QA:aa511bb46450e8416267ab84 | QAG:bc3b792f33ca27b4ea840364 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Among the 71 patients with CRC, 30 had received prior therapies including a fluoropyrimidine, oxaliplatin, and irinotecan, 25 had received bevacizumab, seven had received cetuximab, while six had received multi-kinase inhibitors that target vascular endothelial growth ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:41c3a00e8bb746ad5466f307","quotes":["Among the 71 patients with CRC, 30 had received prior therapies including a ... | [
"CLM:41c3a00e8bb746ad5466f307",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10772321"
] | [
"SPAN:21a9a75472aab3370c9e0fca"
] | [] | [] | {"qa_id":"QA:aa511bb46450e8416267ab84","qa_group_id":"QAG:bc3b792f33ca27b4ea840364","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Among the 71 patients with CRC, 30 had received prior therapies in... |
QA:adcb2ac815f779da6826473b | QAG:b307ad0ab87a2022f7d93d86 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection were examined with flow cytometry as in Figure 1"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f3a31083af30c0eda4e8c3fd","quotes":["PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection we... | [
"CLM:f3a31083af30c0eda4e8c3fd",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC8262295"
] | [
"SPAN:161633d8be95140cce1f47d2"
] | [] | [] | {"qa_id":"QA:adcb2ac815f779da6826473b","qa_group_id":"QAG:b307ad0ab87a2022f7d93d86","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"PBLs, LNLs, and TILs from 21 CRC patients who received surgical re... |
QA:b0fed6c62e7d266550ecf78c | QAG:2f8014ef5bf5cef09e07a11d | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Among the 71 patients with CRC, 30 had received prior therapies including a fluoropyrimidine, oxaliplatin, and irinotecan, 25 had received bevacizumab, seven had received cetuximab, while six had received multi-kinase inhibitors that target vascular endothelial growth ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8458a6f003f01463e333d52d","quotes":["Among the 71 patients with CRC, 30 had received prior therapies including a ... | [
"CLM:8458a6f003f01463e333d52d",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10772321"
] | [
"SPAN:21a9a75472aab3370c9e0fca"
] | [] | [] | {"qa_id":"QA:b0fed6c62e7d266550ecf78c","qa_group_id":"QAG:2f8014ef5bf5cef09e07a11d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Among the 71 patients with CRC, 30 had received prior therapies in... |
QA:b0ff726129e38a380da971a1 | QAG:1e6a6628b3bae33f48946d6f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection were prepared, and the TCR sequencing was performed with next-generation sequencing. ( A ) Diversity of the TCR repertoire in PBLs, LNLs, and TILs evaluated with Shannon’s index"? Return the orig... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3787510112544d50cbaa3fed","quotes":["PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection we... | [
"CLM:3787510112544d50cbaa3fed",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC8262295"
] | [
"SPAN:ca2180707de2e4546115d868"
] | [] | [] | {"qa_id":"QA:b0ff726129e38a380da971a1","qa_group_id":"QAG:1e6a6628b3bae33f48946d6f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"PBLs, LNLs, and TILs from 21 CRC patients who received surgical re... |
QA:b591016cf7e8997de11d7c73 | QAG:96d21d1e7552a689a2feebfc | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Although the association between neutrophil infiltration and response to immunotherapy or survival outcome is controversial, we found that a higher abundance of neutrophils in the tumor microenvironment was associated with the response to PD-1/PD-L1 blockade, which may... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c9cb082d6a3daa10dd26ac62","quotes":["Although the association between neutrophil infiltration and response to imm... | [
"CLM:c9cb082d6a3daa10dd26ac62",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:d1ec5f9eb491a9df7180e6dc"
] | [] | [] | {"qa_id":"QA:b591016cf7e8997de11d7c73","qa_group_id":"QAG:96d21d1e7552a689a2feebfc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Although the association between neutrophil infiltration and respo... |
QA:b8160deb4c0c4f188659c379 | QAG:6720b0e5b45d688962dcfc9c | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "We previous show that ZG16 expression was decreased in colorectal cancer compared to normal tissue"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3c3e5259e6f4793dc0e14b31","quotes":["We previous show that ZG16 expression was significantly decreased in colorec... | [
"CLM:3c3e5259e6f4793dc0e14b31",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC7773682"
] | [
"SPAN:a8c32d94d27832ca732ae811"
] | [] | [] | {"qa_id":"QA:b8160deb4c0c4f188659c379","qa_group_id":"QAG:6720b0e5b45d688962dcfc9c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"We previous show that ZG16 expression was decreased in colorectal ... |
QA:b9c3da11e059319ad7e5fd7e | QAG:68620147a163d8e3b72f0801 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Nivolumab ± ipilimumab or pembrolizumab alone were recommended for neoadjuvant treatments for resectable or unresectable synchronous liver and/or lung metastastic dMMR/MSI-H CRC by the NCCN guideline ( 9 , 10 ), and for primary treatments for unresectable metachronous ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ca96453c9df0277153d763b6","quotes":["Nivolumab ± ipilimumab or pembrolizumab alone were ... | [
"CLM:ca96453c9df0277153d763b6",
"CLM:439debb91a7c2319411d2844",
"CLM:91e6a32caa40f84b08f4c40e",
"CLM:91f035f0a3e5b22bf5c8bdc7",
"CLM:3066c16d52bd5dfefcc64730"
] | [
"PMCID:PMC8714781",
"PMCID:PMC6984585",
"PMCID:PMC9496787"
] | [
"SPAN:607f359d4b02a1022877e697",
"SPAN:706e106952b373b93b4ddaff",
"SPAN:e5eafaacd07531f0c9c28cf6",
"SPAN:bb1f8e5c077ed3a129b35773"
] | [
"ASC2:1b326b927991e49ca6afeb85",
"ASC2:381323b8ce032a46326df48f"
] | [
"HYP:DCH:6b91d76f720bd7fb20f3e727"
] | {"qa_id":"QA:b9c3da11e059319ad7e5fd7e","qa_group_id":"QAG:68620147a163d8e3b72f0801","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Nivolumab ± ipilimumab or pembrolizumab alone were recommended for... |
QA:ba1d18810022ef90783efd61 | QAG:240c3c84bc1f0ae19997857a | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Our results also showed that patients with BRAF -mutant CRC who received dual-drug immunotherapy achieved a better ORR than those who received single-drug immunotherapy ( P1 ═ 0.006)"? Return the original wording with paper, Claim, and Evidence Span references.
Integr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9fdaa369d9233543746f8348","quotes":["Our results also showed that patients with BRAF -mutant CRC who received dua... | [
"CLM:9fdaa369d9233543746f8348",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10113953"
] | [
"SPAN:b553d7cb74f3360462cb7454"
] | [] | [] | {"qa_id":"QA:ba1d18810022ef90783efd61","qa_group_id":"QAG:240c3c84bc1f0ae19997857a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Our results also showed that patients with BRAF -mutant CRC who re... |
QA:ba23cc8d4137e1b9c1110d59 | QAG:1d3eb6881600f94b70775216 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In bivariate analysis, elevated expression of cGAS and STING in cancer cells was associated with MSI-H colon cancer (Fisher’s exact test, both p = 0.0203)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f6d868ff133bfe42ae781167","quotes":["In bivariate analysis, elevated expression of cGAS and STING in cancer cells... | [
"CLM:f6d868ff133bfe42ae781167",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9818394"
] | [
"SPAN:d40660bdb7f92ee6b45c8fff"
] | [] | [] | {"qa_id":"QA:ba23cc8d4137e1b9c1110d59","qa_group_id":"QAG:1d3eb6881600f94b70775216","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In bivariate analysis, elevated expression of cGAS and STING in ca... |
QA:bcfa1487a69ddc93e0b49b22 | QAG:5e34fb6d613b50779ed325f1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "1 months for dMMR/MSI-H metastatic CRC patients who received pembrolizumab after one or more prior treatments"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with pa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:194f9d230043c611cb6689f2","quotes":["From the KEYNOTE-164 study, the median progression-free survival (PFS) was 4... | [
"CLM:194f9d230043c611cb6689f2",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:31c875744ac7e4350dd35f3a"
] | [] | [] | {"qa_id":"QA:bcfa1487a69ddc93e0b49b22","qa_group_id":"QAG:5e34fb6d613b50779ed325f1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"1 months for dMMR/MSI-H metastatic CRC patients who received pembr... |
QA:bd17bdf90bc2081ab7114a27 | QAG:bbf937e4bcae2c3fa448163e | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Methods In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorour... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a145d18a76d5fd2967fb4ee7","quotes":["Methods In this phase 3, open-label trial, 307 patients with metastatic MSI-... | [
"CLM:a145d18a76d5fd2967fb4ee7",
"CLM:439debb91a7c2319411d2844"
] | [
"PMID:33264544"
] | [
"SPAN:9802eb16e4af7423873d91d8"
] | [] | [] | {"qa_id":"QA:bd17bdf90bc2081ab7114a27","qa_group_id":"QAG:bbf937e4bcae2c3fa448163e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Methods In this phase 3, open-label trial, 307 patients with metas... |
QA:be7a5bc419cc5744d2bfdc95 | QAG:479104c9355c81dfd19b58b3 | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:37245872? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable an... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMID:37245872","verdict":"no_released_traceable_claim","reason":"No Cla... | [] | [
"PMID:37245872"
] | [] | [] | [] | {"qa_id":"QA:be7a5bc419cc5744d2bfdc95","qa_group_id":"QAG:479104c9355c81dfd19b58b3","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMID:37245872? E... |
QA:c0c503c0c8463944cedbdc0b | QAG:0a5fff874816132daf71e4a0 | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9492301? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9492301","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9492301"
] | [] | [] | [] | {"qa_id":"QA:c0c503c0c8463944cedbdc0b","qa_group_id":"QAG:0a5fff874816132daf71e4a0","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9492301... |
QA:c32f02728dcc1e64db4d8547 | QAG:0505866d6d72aea590cad273 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "CMTM6 expression was correlated with PD-L1 expression and CD163 + M2 macrophage density in dMMR CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:568f7982c38335db104cd206","quotes":["CMTM6 expression was positively correlated with PD-L1 expression and CD163 +... | [
"CLM:568f7982c38335db104cd206",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:4761cc37fbc2c80cdb54b0ca"
] | [] | [] | {"qa_id":"QA:c32f02728dcc1e64db4d8547","qa_group_id":"QAG:0505866d6d72aea590cad273","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"CMTM6 expression was correlated with PD-L1 expression and CD163 + ... |
QA:c491a81c250018ab57c83532 | QAG:5c98c5eabcd425d2bb0105c6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "We collected data for 32 patients with refractory/metastatic CRC who received PD-1/PD-L1 inhibitors, including 6 dMMR patients and 26 pMMR patients (Supplementary Table 9)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated proven... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:87f32ef4ce9c1b27ccbc1f17","quotes":["We collected data for 32 patients with refractory/metastatic CRC who receive... | [
"CLM:87f32ef4ce9c1b27ccbc1f17",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:9d0c0e80ced79b58295fc2ea"
] | [] | [] | {"qa_id":"QA:c491a81c250018ab57c83532","qa_group_id":"QAG:5c98c5eabcd425d2bb0105c6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"We collected data for 32 patients with refractory/metastatic CRC w... |
QA:c9ca05094a1d3fd83a1a5e01 | QAG:2a530614fdda6687cf919177 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The results further validated that CMTM6 expression was correlated with PD-L1 in CRC ( P < 0.001) (Fig. 7 d)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with pap... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:25c1b4dafb327a23bdde44f0","quotes":["The results further validated that CMTM6 expression was positively correlate... | [
"CLM:25c1b4dafb327a23bdde44f0",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:2c4b710756b106c58eb4be7d"
] | [] | [] | {"qa_id":"QA:c9ca05094a1d3fd83a1a5e01","qa_group_id":"QAG:2a530614fdda6687cf919177","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The results further validated that CMTM6 expression was correlated... |
QA:ccbb10fbb65ef095653e828f | QAG:45a66225a194ff8fb5f634d6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Loss of ZG16 was associated with molecular and clinicopathological phenotypes of colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:57a98da7a9da3f515a5f6605","quotes":["5. Meng H., Li W., Boardman L.A., Wang L. Loss of ZG16 is associated with mo... | [
"CLM:57a98da7a9da3f515a5f6605",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC7773682"
] | [
"SPAN:022a49d141b9ed696963bebd"
] | [] | [] | {"qa_id":"QA:ccbb10fbb65ef095653e828f","qa_group_id":"QAG:45a66225a194ff8fb5f634d6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Loss of ZG16 was associated with molecular and clinicopathological... |
QA:cd02e0e59cd6cf9b0c27efc0 | QAG:86ea54b1df4cc7bbd0db305f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Mouse experiments demonstrated that IL-1β-driven MDSC infiltration suppressed the accumulation of CD8 + T cells, which increased the anti-PD-1 resistance of MSI-H/dMMR CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated proven... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8bf4debcfd3d0ff32c928455","quotes":["Mouse experiments demonstrated that IL-1β-driven MDSC infiltration suppresse... | [
"CLM:8bf4debcfd3d0ff32c928455",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC10142806"
] | [
"SPAN:606d098cc03c967fa91d9d96"
] | [] | [] | {"qa_id":"QA:cd02e0e59cd6cf9b0c27efc0","qa_group_id":"QAG:86ea54b1df4cc7bbd0db305f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Mouse experiments demonstrated that IL-1β-driven MDSC infiltration... |
QA:cd3ce7b4773f6c19d546679d | QAG:c1e533d6de1b85a54f47d832 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Conclusions : Neoadjuvant PD-1 blockade promoted tumor regression with a major clinical and pathological response in advanced dMMR/MSI-H colorectal cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6bfe82dd6dbd2ecb9df190dd","quotes":["Conclusions : Neoadjuvant PD-1 blockade induced tumor regression with a majo... | [
"CLM:6bfe82dd6dbd2ecb9df190dd",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC6984585"
] | [
"SPAN:029102afdaa609266a66afee"
] | [] | [] | {"qa_id":"QA:cd3ce7b4773f6c19d546679d","qa_group_id":"QAG:c1e533d6de1b85a54f47d832","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Conclusions : Neoadjuvant PD-1 blockade promoted tumor regression ... |
QA:ce3f1d7167d2fb798f161418 | QAG:f637c64acd073f62f6f0f665 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "CMTM6 and PD-L1 expression and CD4 + , CD8 + , CD68 + or CD163 + cell density was higher than dMMR CRC patients than in pMMR CRC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exac... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:da0db772f6fa557a60b2737c","quotes":["CMTM6 and PD-L1 expression and CD4 + , CD8 + , CD68 + or CD163 + cell densit... | [
"CLM:da0db772f6fa557a60b2737c",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:667b25a3262d7ba38c3fa52c"
] | [] | [] | {"qa_id":"QA:ce3f1d7167d2fb798f161418","qa_group_id":"QAG:f637c64acd073f62f6f0f665","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"CMTM6 and PD-L1 expression and CD4 + , CD8 + , CD68 + or CD163 + c... |
QA:cf18b6b2df54ef234967482f | QAG:a99e40ab6bbeabf99b1c9e0b | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "We conclude that despite being a marker of improved prognosis in stage II, dMMR was not associated with a favorable prognosis in stage III colon cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:956a26b7600cc18c8a841285","quotes":["We conclude that despite being a marker of improved prognosis in stage II, d... | [
"CLM:956a26b7600cc18c8a841285"
] | [
"PMCID:PMC9468812"
] | [
"SPAN:e4d2074d06503c4484327664"
] | [] | [] | {"qa_id":"QA:cf18b6b2df54ef234967482f","qa_group_id":"QAG:a99e40ab6bbeabf99b1c9e0b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"We conclude that despite being a marker of improved prognosis in s... |
QA:d03161e8125c95c2bb6baa19 | QAG:4cc0faa044cb9dd10408f26c | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Conclusion Anti-PD-1/PD-L1 therapy in MSI-H/dMMR advanced CRC was associated with improved survival"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:68cd7ef2165011358edb0dda","quotes":["Conclusion Anti-PD-1/PD-L1 therapy in MSI-H/dMMR advanced CRC was associated... | [
"CLM:68cd7ef2165011358edb0dda",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9549670"
] | [
"SPAN:467a2dd15cb2575e6019b68f"
] | [] | [] | {"qa_id":"QA:d03161e8125c95c2bb6baa19","qa_group_id":"QAG:4cc0faa044cb9dd10408f26c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Conclusion Anti-PD-1/PD-L1 therapy in MSI-H/dMMR advanced CRC was ... |
QA:d040fbf4a9a660bfa47164e9 | QAG:0a7e4d974e11a0ddb97d8833 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Among the 71 patients with CRC, 30 had received prior therapies including a fluoropyrimidine, oxaliplatin, and irinotecan, 25 had received bevacizumab, seven had received cetuximab, while six had received multi-kinase inhibitors that target vascular endothelial growth ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8badf73f3ef2335dca254bbb","quotes":["Among the 71 patients with CRC, 30 had received prior therapies including a ... | [
"CLM:8badf73f3ef2335dca254bbb",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10772321"
] | [
"SPAN:21a9a75472aab3370c9e0fca"
] | [] | [] | {"qa_id":"QA:d040fbf4a9a660bfa47164e9","qa_group_id":"QAG:0a7e4d974e11a0ddb97d8833","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Among the 71 patients with CRC, 30 had received prior therapies in... |
QA:d1243df13330ed737d1df0f3 | QAG:8889785a322cee3ac993f389 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The 276 patients from the Norwegian Gastrointestinal Cancer Group (NGICG) material were included between 1993 and 1996 ( 11 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:439debb91a7c2319411d2844","quotes":["The 276 patients from the Norwegian Gastrointestinal Cancer Group (NGICG) ma... | [
"CLM:439debb91a7c2319411d2844",
"CLM:02b542ecdd30313379778da4"
] | [
"PMCID:PMC9468812"
] | [
"SPAN:8f7642d9a142d554de5f1d92"
] | [] | [] | {"qa_id":"QA:d1243df13330ed737d1df0f3","qa_group_id":"QAG:8889785a322cee3ac993f389","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The 276 patients from the Norwegian Gastrointestinal Cancer Group ... |
QA:d5b67c539766c16ecbd7070d | QAG:79cd9976092df6a07d567b1b | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Bioinformatics analysis further showed that CMTM6 expression was correlated with PD-L1 in CRC ( P < 0.001) and CMTM6 expression correlated with M2 macrophage-related gene [CD163 ( P < 0.001), CD206 ( P < 0.001), IL-10 ( P < 0.001), STAT3 ( P < 0.001), IL-33 ( P < 0.001... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2665338177a79546344dc4f3","quotes":["Bioinformatics analysis further showed that CMTM6 expression was positively ... | [
"CLM:2665338177a79546344dc4f3",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:fa5acaa1c451580cee5773bb"
] | [] | [] | {"qa_id":"QA:d5b67c539766c16ecbd7070d","qa_group_id":"QAG:79cd9976092df6a07d567b1b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Bioinformatics analysis further showed that CMTM6 expression was c... |
QA:d9f82ecd604ddd0fcd765322 | QAG:6081eac517bebcb35b25aac4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Results For predicting survival among patients with MMR-d advanced colorectal cancer receiving PD-1 blockade, cell-to-cell distance measurements, but not cell densities or ratios achieved statistical significance univariately"? Return the original wording with paper, C... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:db72b6149c966c0c54cdaeb4","quotes":["Results For predicting survival among patients with MMR-d advanced colorecta... | [
"CLM:db72b6149c966c0c54cdaeb4",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC10592158"
] | [
"SPAN:69f8f8f42ae586d71a83ecce"
] | [] | [] | {"qa_id":"QA:d9f82ecd604ddd0fcd765322","qa_group_id":"QAG:6081eac517bebcb35b25aac4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Results For predicting survival among patients with MMR-d advanced... |
QA:dabc50b766cf762ba41309bf | QAG:29ce6955edbc582fdecb344f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection were examined with flow cytometry as in Figure 1 . ( A ) Representative flow cytometry staining (upper) and summaries (lower) for the frequency of T-bet– and Eomes–expressing cells in CD8 + T cel... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ed71b40ca0b96a082a282323","quotes":["PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection we... | [
"CLM:ed71b40ca0b96a082a282323",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC8262295"
] | [
"SPAN:5dcd9d129518bedf6818d6ea"
] | [] | [] | {"qa_id":"QA:dabc50b766cf762ba41309bf","qa_group_id":"QAG:29ce6955edbc582fdecb344f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"PBLs, LNLs, and TILs from 21 CRC patients who received surgical re... |
QA:dbf2cf7979f6017258ada652 | QAG:55640ed4f36eb56e495d81cd | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Moreover, CMTM6 expression in TCs and ICs was correlated with CD68 + macrophage and CD163 + M2 macrophage density in dMMR CRC but not in pMMR CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:222651d3d220686df6a48998","quotes":["Moreover, CMTM6 expression in TCs and ICs was positively correlated with CD6... | [
"CLM:222651d3d220686df6a48998",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:8654fc3e3025ee8d9c48f5b1"
] | [] | [] | {"qa_id":"QA:dbf2cf7979f6017258ada652","qa_group_id":"QAG:55640ed4f36eb56e495d81cd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Moreover, CMTM6 expression in TCs and ICs was correlated with CD68... |
QA:ddb8f090cc655ddbcb991463 | QAG:4b65e5674ccd9432f90e744d | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "The response rate of PD-1/PD-L1 inhibitors predicted according to CMTM6 expression in CD163 + M2 macrophages was 66.7% (2/3) in dMMR CRC patients and 75% (3/4) in pMMR CRC patients"? Return the original wording with paper, Claim, and Evidence Span references.
Integrat... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a90a01b9d98b5bd4e4f73f2c","quotes":["The response rate of PD-1/PD-L1 inhibitors predicted according to CMTM6 expr... | [
"CLM:a90a01b9d98b5bd4e4f73f2c",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:59956b6dd35ce68854194dbc"
] | [] | [] | {"qa_id":"QA:ddb8f090cc655ddbcb991463","qa_group_id":"QAG:4b65e5674ccd9432f90e744d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"The response rate of PD-1/PD-L1 inhibitors predicted according to ... |
QA:de91aec9261082adefcc7fcd | QAG:68ed5581f40b125292c3da02 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection were prepared, and immunological phenotypes were examined with flow cytometry"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ea5aa08a13b00e7c53cf68ef","quotes":["PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection we... | [
"CLM:ea5aa08a13b00e7c53cf68ef",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC8262295"
] | [
"SPAN:d0e00af01e396126cb60969b"
] | [] | [] | {"qa_id":"QA:de91aec9261082adefcc7fcd","qa_group_id":"QAG:68ed5581f40b125292c3da02","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"PBLs, LNLs, and TILs from 21 CRC patients who received surgical re... |
QA:dea3d91c979f3a14b6b25b27 | QAG:47cf8ea7ba111cc7f3dc9722 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In stage II colon cancer, there was a tendency toward improved DFS for dMMR patients (dMMR: 57.14 (95% CI 54.66–59.62) vs. pMMR 53.54 (95% CI 51.48–55.60), p=0.015, multivariate Cox regression HR 0.24 (95% CI 0.06-1.04), p=0.057)"? Return the original wording with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c28d0685cb2816fe649b1423","quotes":["In stage II colon cancer, there was a tendency toward improved DFS for dMMR ... | [
"CLM:c28d0685cb2816fe649b1423"
] | [
"PMCID:PMC9468812"
] | [
"SPAN:0abfba10ff3d398a22f98442"
] | [] | [] | {"qa_id":"QA:dea3d91c979f3a14b6b25b27","qa_group_id":"QAG:47cf8ea7ba111cc7f3dc9722","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In stage II colon cancer, there was a tendency toward improved DFS... |
QA:e55e1ffb05e5b695771267f1 | QAG:da798ed5a782391d2aad2efc | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "CMTM6 expression in TCs and ICs was correlated with CD68 + macrophage density ( r = 0.200, P = 0.028 and r = 0.222, P = 0.015, respectively) and CD163 + M2 macrophage density ( r = 0.095, P = 0.026 and r = 0.292, P = 0.001, respectively) in dMMR CRC but not in pMMR CRC... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:5e38d5410a710ad05ff62481","quotes":["CMTM6 expression in TCs and ICs was positively correlated with CD68 + macrop... | [
"CLM:5e38d5410a710ad05ff62481",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8505364"
] | [
"SPAN:518de1fa024accebe75818ca"
] | [] | [] | {"qa_id":"QA:e55e1ffb05e5b695771267f1","qa_group_id":"QAG:da798ed5a782391d2aad2efc","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"CMTM6 expression in TCs and ICs was correlated with CD68 + macroph... |
QA:e59e7aabbbb9abe2658dea5f | QAG:0e084c4c4c335dd84d07ecb9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In a previous study from our center, 29 patients with MSI-H/dMMR locally advanced colorectal cancer received neoadjuvant immunotherapy with a single-agent PD-1 inhibitor, and the ORR was 100% (29/29), consistent with the results of the NICHE study"? Return the original... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a17b5d1a2a868798b4e8707b","quotes":["In a previous study from our center, 29 patients wi... | [
"CLM:a17b5d1a2a868798b4e8707b",
"CLM:439debb91a7c2319411d2844",
"CLM:37f62821a99d472126d5ed39"
] | [
"PMCID:PMC10142806",
"PMCID:PMC9988634"
] | [
"SPAN:ee3f6b8a83da99edce046e7f",
"SPAN:2565648bd4a35a448a6e4baf"
] | [
"ASC2:aa45919a80aedaf51bf0f06d"
] | [] | {"qa_id":"QA:e59e7aabbbb9abe2658dea5f","qa_group_id":"QAG:0e084c4c4c335dd84d07ecb9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In a previous study from our center, 29 patients with MSI-H/dMMR l... |
QA:e7039851dfe9c9a51cabf519 | QAG:71f5d9e0312ec97d1082922b | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Our results also showed that patients with BRAF -mutant CRC who received dual-drug immunotherapy achieved a better ORR than those who received single-drug immunotherapy ( P1 ═ 0.006)"? Return the original wording with paper, Claim, and Evidence Span references.
Integr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6366998d9377fdfc0b0bff75","quotes":["Our results also showed that patients with BRAF -mutant CRC who received dua... | [
"CLM:6366998d9377fdfc0b0bff75",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10113953"
] | [
"SPAN:b553d7cb74f3360462cb7454"
] | [] | [] | {"qa_id":"QA:e7039851dfe9c9a51cabf519","qa_group_id":"QAG:71f5d9e0312ec97d1082922b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Our results also showed that patients with BRAF -mutant CRC who re... |
QA:e7117a307cdad459d905d8dc | QAG:48801c25fb8f87c129d2314f | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "PD-1 blockade has improved the survival of metastatic colorectal cancer with DNA Mismatch Repair-Deficient (dMMR)/Microsatellite Instability-High (MSI-H)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements:... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bcfb8362538d1d02f96a1465","quotes":["PD-1 blockade has significantly improved the survival of metastatic colorect... | [
"CLM:bcfb8362538d1d02f96a1465",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC6984585"
] | [
"SPAN:30536ee0a724d6d32c446257"
] | [] | [] | {"qa_id":"QA:e7117a307cdad459d905d8dc","qa_group_id":"QAG:48801c25fb8f87c129d2314f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"PD-1 blockade has improved the survival of metastatic colorectal c... |
QA:eac95002cf00d704e8e52bc2 | QAG:7bba7077ae96d90b73ebe94e | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Introduction Deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) was associated with an improved prognosis in colon cancer stage II but poor prognosis in stage IV colon cancer"? Return the original wording with paper, Claim, and Evidence Span re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:afb19a9ce23d5b6709ca5792","quotes":["Introduction Deficient mismatch repair (dMMR) or high microsatellite instabi... | [
"CLM:afb19a9ce23d5b6709ca5792"
] | [
"PMCID:PMC9468812"
] | [
"SPAN:1f5d6626dc64096e7de744e5"
] | [] | [] | {"qa_id":"QA:eac95002cf00d704e8e52bc2","qa_group_id":"QAG:7bba7077ae96d90b73ebe94e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Introduction Deficient mismatch repair (dMMR) or high microsatelli... |
QA:f0291e603c629bb7e2867868 | QAG:2869ad88c512ad6230980dc2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "2, randomized Clinical stage II-III LARC 185 (MSI status NA) FOLFOX → CRT ± pembrolizumab × 4 months → surgery 29% ExiST Phase 2, single arm Clinical stage II-III-IV rectal cancer 37 pMMR/MSI-L + 1 dMMR/MSI-H galunisertib → CRT + galunisertib → surgery if cCR-, otherwi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e692f44cc74d9ca9b037b886","quotes":["Study Name Experimental Setting Study Population Tr... | [
"CLM:e692f44cc74d9ca9b037b886",
"CLM:439debb91a7c2319411d2844",
"CLM:5c6302925273f870dced07e0"
] | [
"PMCID:PMC9496787",
"PMCID:PMC9582482"
] | [
"SPAN:77e68a141ee38d9637b99575",
"SPAN:0cd72c237f61acad933d50db",
"SPAN:25dbf4a61b0680baf4713d35"
] | [
"ASC2:0f5bc5e72027332e43b37bcb"
] | [
"HYP:DCH:5921de441b0b233d89816b36"
] | {"qa_id":"QA:f0291e603c629bb7e2867868","qa_group_id":"QAG:2869ad88c512ad6230980dc2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"2, randomized Clinical stage II-III LARC 185 (MSI status NA) FOLFO... |
QA:f21740df6352b89ceaa5a7b6 | QAG:66dec2c91803e337be0c62fc | provenance_qa | paper_evidence_availability | provenance_qa | G007 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8944161? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8944161","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8944161"
] | [] | [] | [] | {"qa_id":"QA:f21740df6352b89ceaa5a7b6","qa_group_id":"QAG:66dec2c91803e337be0c62fc","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G007","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8944161... |
QA:f322ead54c5d3c4662f3f53b | QAG:6445694e3550f7d7e55cf0fd | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "In one clinical trial of CRC, the ORR of 41 patients who received third-line immunotherapy was 31.7%, while that of 24 patients who received second-line immunotherapy was 62.5%"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7ce6316df8f7d73ef100a4d5","quotes":["In one clinical trial of CRC, the ORR of 41 patients who received third-line... | [
"CLM:7ce6316df8f7d73ef100a4d5",
"CLM:348c7a61fb91d919ec827c93"
] | [
"PMCID:PMC10113953"
] | [
"SPAN:cf363a7eca5c9328e5a93004"
] | [] | [] | {"qa_id":"QA:f322ead54c5d3c4662f3f53b","qa_group_id":"QAG:6445694e3550f7d7e55cf0fd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"In one clinical trial of CRC, the ORR of 41 patients who received ... |
QA:f3a2c004311ed513b7e6e62a | QAG:4067e4c1a33cecc7bde999b5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "Patients who withdrew consent due to symptomatic deterioration before disease evaluation were included in the non-responder group"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppor... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fec333483635bf3d2b0ad491","quotes":["Patients who withdrew consent due to symptomatic deterioration before diseas... | [
"CLM:fec333483635bf3d2b0ad491",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC9582482"
] | [
"SPAN:31c875744ac7e4350dd35f3a",
"SPAN:592c3a332889ffd930f5ae80"
] | [] | [] | {"qa_id":"QA:f3a2c004311ed513b7e6e62a","qa_group_id":"QAG:4067e4c1a33cecc7bde999b5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"Patients who withdrew consent due to symptomatic deterioration bef... |
QA:f5692a7fc92ee94e8a2829f5 | QAG:08d20ccad2738617684ed532 | provenance_qa | exact_evidence_retrieval | provenance_qa | G007 | en | train | Which exact source passage supports the statement "PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection were examined with flow cytometry as in Figure 1 . ( A ) Representative flow cytometry staining (left) and summaries (right) for the frequency of PD-1–expressing cells in CD4 + and CD8 + T cells ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ffcd6132a236e9d311997ab1","quotes":["PBLs, LNLs, and TILs from 21 CRC patients who received surgical resection we... | [
"CLM:ffcd6132a236e9d311997ab1",
"CLM:439debb91a7c2319411d2844"
] | [
"PMCID:PMC8262295"
] | [
"SPAN:83f37bdf31eb5428438d8fa6"
] | [] | [] | {"qa_id":"QA:f5692a7fc92ee94e8a2829f5","qa_group_id":"QAG:08d20ccad2738617684ed532","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G007","question":"Which exact source passage supports the statement \"PBLs, LNLs, and TILs from 21 CRC patients who received surgical re... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.